文献速递肝病炎症性肠病消化道肿瘤与早癌

基于人群的原发性硬化性胆管炎合并炎症性肠病队列中肝胆胰癌风险解读

Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort.
PubMed 文献 · Hepatology · 2026-02-04

该研究利用加拿大安大略省2002至2018年卫生行政数据库,纳入476例新发原发性硬化性胆管炎合并炎症性肠病(PSC-IBD)患者并随访至2021年,描述肝胆胰癌(HPBCa)负担。10年无事件生存概率为54%,约1/20发生HPBCa相关结局,高达1/4发生非HPBCa相关移植或死亡,13%经历多次事件。年龄与HPBCa相关(HR 1.02,95%CI 1.01-1.04),结肠切除后(TIR 3.08,95%CI 1.7-5.59)和胆囊切除后(TIR 3.85,95%CI 2.21-6.64)死亡率更高,但术后癌症或移植发生率无差异。

要点

  • PSC-IBD患者10年无事件概率54%,约1/20发生HPBCa相关结局。
  • 年龄与HPBCa风险相关(HR 1.02,95%CI 1.01-1.04),性别无关联。
  • 结肠切除和胆囊切除后死亡率更高,但术后癌症或移植发生率无差异。

核心结论

  • 部分PSC-IBD患者可长期无事件,但很大比例仍发生疾病相关癌症、结肠切除、胆囊切除和移植事件。
  • 术后更高死亡率可能反映促使手术的潜在疾病过程(如异型增生/恶性肿瘤、难治性IBD),而非手术本身。

研究设计与样本

  • 基于人群的回顾性队列研究,利用加拿大安大略省关联卫生行政数据库(2002-2018年),随访至2021年。
  • 纳入476例新发PSC-IBD个体,采用多状态马尔可夫模型评估转移概率和转移强度比(TIR)。

主要发现

  • 10年无事件生存概率为54%。
  • 约1/20发生HPBCa相关结局(诊断或死亡),高达1/4发生非HPBCa相关移植或死亡。
  • 随访期间13%经历多次事件。
  • 年龄与HPBCa相关(HR 1.02,95%CI 1.01-1.04),性别无关联。
  • 结肠切除后死亡率TIR 3.08(95%CI 1.7-5.59),胆囊切除后死亡率TIR 3.85(95%CI 2.21-6.64),但术后癌症或移植发生率无差异。

临床怎么用

  • 了解PSC-IBD疾病轨迹变异有助于个体化管理和患者咨询。
  • 术后死亡率升高应结合促使手术的潜在疾病过程解读,而非归因于手术本身。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a pre-malignant condition with elevated risk of hepatopancreatobiliary cancers (HPBCa) and colorectal cancer (CRC) when inflammatory bowel disease (IBD) is present. We described cancer burden in a contemporary PSC-IBD cohort, and assessed rates of subsequent cancers, liver transplant, and death post-colectomy or post-cholecystectomy status. METHODS: Using linked health administrative databases, we calculated cause-specific cumulative incidences of HPBCa-related outcomes (diagnoses/deaths) and non-HPBCa-related transplant/death among individuals with PSC-IBD in Ontario, Canada (2002-2018), followed to 2021. Transition probabilities and transition intensity ratios (TIR) were evaluated using a multistate Markov model. RESULTS: Among 476 individuals with incident PSC-IBD, there was a 54% probability of remaining event-free at 10 years. Approximately 1 in 20 experienced an HPBCa-related outcome, and up to 1 in 4 had a non-HPBCa-related transplant/death. During follow-up, 13% experienced multiple events. Age was associated with HPBCa (HR 1.02, 95% CI 1.01-1.04), but not sex. Mortality occurred more frequently post-colectomy (TIR 3.08, 95% CI 1.7-5.59) and post-cholecystectomy (TIR 3.85, 95% CI 2.21-6.64) relative to event-free PSC-IBD, but there were no differences in post-surgery incidence of cancer or transplant. CONCLUSIONS: While some individuals with PSC-IBD experienced an extended event-free disease course, a large proportion experienced disease-related cancer, colectomy, cholecystectomy, and transplant events. Higher mortality rates observed after surgery were likely related to underlying disease processes that motivated surgical intervention (eg, dysplasia/malignancy, refractory IBD), rather than the surgery itself. Understanding how PSC-IBD disease trajectories vary can inform individual management and patient counselling.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Leung KK, Li W, Hansen B, et al. Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort. Hepatology. 2026. PMID: 41637315. doi:10.1097/HEP.0000000000001692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。